Eagle Pharmaceuticals Inc (NASDAQ: EGRX) stock closed at $5.20 on 4/15/24 after a major increase of 13.3%. Moreover, this advance was accompanied by exceptionally high trading volume at 210% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 1.6% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, EGRX is expected to continue to be a modest Value Builder.
Eagle Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Eagle Pharmaceuticals has a very high Appreciation Score of 98 but a very low Power Rating of 7, and the Neutral Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment